Featured News
Associate Professor Vishal Patel, a dermatologist, says many factors explain the surge in skin cancer rates.
Of more than 500 occupations in the United States, flight attendants and pilots have the highest and second-highest proportion of radiation-related cancer deaths, a new study has found.
The results support considering occupational radiation protections for U.S. aircrew members commensurate with…
Key Takeaways
Melanin offers some UV protection but doesn't prevent skin damage or cancer in Black skin.
La Roche-Posay's grant supports diverse dermatology research addressing skin-of-color gaps and inclusivity.
Advancements in technology, education, and research aim to improve dermatology care…
Hormonal shifts can make you sweat more — and even change the way you smell.
Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.
The panel discusses how to navigate treatment selection when patients have preferences and how to compare the available advanced therapies.
Dr. Patel presents the program's first case: a 78-year-old woman with an enlarging, ulcerated lesion on the right temple and preauricular area, measuring close to five centimeters.
The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
Applied twice daily, Eucrisa is a phosphodiesterase 4 (PDE-4) inhibitor. Its precise mechanism of action in atopic dermatitis, however,…
Infection is among the most clinically consequential and underappreciated comorbidities in atopic dermatitis (AD), according to , Adam Friedman, MD, FAAD, who addressed the topic in a presentation at the Revolutionizing Atopic Dermatitis 2026 Conference in Nashville, Tennessee. The relationship, he…
Over 15 years, advanced cutaneous squamous cell carcinoma has moved from limited chemotherapy and EGFR inhibition to checkpoint blockade. Dr. Chandra and Dr. Patel trace how the 2018 approvals restructured treatment sequencing and the timing of oncologic involvement.
